The Scientist

» FDA and disease/medicine

Most Recent

image: Califf Vacates FDA’s Top Post

Califf Vacates FDA’s Top Post

By | January 20, 2017

Robert Califf steps down as FDA Commissioner as Donald Trump takes office.

0 Comments

image: Exploring the Epigenetics of Ethnicity

Exploring the Epigenetics of Ethnicity

By | January 11, 2017

Researchers attempt to estimate how much of the human genome’s methylation patterns can be attributed to genetic ancestry.

0 Comments

image: Drug Approval Timeline Same as 20 Years Ago

Drug Approval Timeline Same as 20 Years Ago

By | January 9, 2017

A report finds that new medications still take about 12 years to go from patent to patient.

0 Comments

image: Contributors

Contributors

By | January 1, 2017

Meet some of the people featured in the January 2017 issue of The Scientist.

0 Comments

image: Pharma Redo

Pharma Redo

By | January 1, 2017

Steve Braun of Cures Within Reach, a nonprofit focused on breathing new life into old medicines, describes the potential benefits of drug repurposing.

1 Comment

image: FDA Approves First Treatment for Spinal Muscular Atrophy

FDA Approves First Treatment for Spinal Muscular Atrophy

By | December 28, 2016

The oligonucleotide therapeutic will soon be available in the U.S.

0 Comments

Oncologists have raised concerns about a mouse study that suggests the vaccine for human papillomavirus could cause brain damage.

0 Comments

image: FDA OKs Clinical Trials of Ecstasy for PTSD

FDA OKs Clinical Trials of Ecstasy for PTSD

By | December 1, 2016

The illicit drug has shown promise in helping people with debilitating post-traumatic stress disorder.

0 Comments

image: Biomedical Research Bill Approved in House

Biomedical Research Bill Approved in House

By | December 1, 2016

The 21st Century Cures Act could provide funds to federal research agencies for the decade and accelerate the drug approval process.

1 Comment

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

Popular Now

  1. Symmetrical Eyes Indicate Dyslexia
  2. German Scientists Resign from Elsevier Journals’ Editorial Boards
  3. Germany Sees Drastic Decrease in Insects
  4. Swapping Cigarettes for Vaping
    The Scientist Swapping Cigarettes for Vaping

    New evidence suggests e-cigarettes are not without risks to human health, but can be useful in getting people to kick their smoking habit.

RayBiotech